Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03874065 · ClinicalTrials.gov registry record
Medical Data Collection in the Formation of Precision Oncology Registry
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 2,885
- Enrollment target
NCT03874065: Clinical Trial study, sponsored by Wake Forest University Health Sciences.
NCT03874065 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 2,885 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03874065 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 2,885 participants
- Enrollment target
Study Summary
In efforts to develop an aggregation point for patient clinical data and data related to DNA sequencing in the Comprehensive Cancer Center, this registry will be developed to provide a comprehensive data store. The goal of the registry will be to collect information on the Cancer Center population undergoing next generation DNA sequencing (NGS) on their tumors or liquid biopsies.
Primary Outcome
To capture characteristics of the patient population undergoing next generation DNA sequencing of their tumor or liquid biopsy for more efficient clinical operations by collecting data on demographics, disease, and previous treatment.
Interventions
- OTHER Medical Chart Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,885 participants |
| Start Date | 2019-05-17 |
| Est. Completion | 2024-01-11 |
Why NCT03874065 stopped before completion
NCT03874065 is an observational study that tracks outcomes without assigning an intervention. Its 2,885 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Medical Chart Review is the first listed.
NCT03874065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03874065 about?
NCT03874065 is a clinical study titled "Medical Data Collection in the Formation of Precision Oncology Registry". In efforts to develop an aggregation point for patient clinical data and data related to DNA sequencing in the Comprehensive Cancer Center, this registry will be developed to provide a comprehensive data store. The goal of the registry will be to collect information on the Cancer Center population u...
What is the current status of trial NCT03874065?
This trial is currently terminated. The enrollment target is 2,885 participants. The study started on 2019-05-17. Estimated completion is 2024-01-11.
What interventions are being tested in trial NCT03874065?
The interventions under investigation include: Medical Chart Review (OTHER).
Who is sponsoring clinical trial NCT03874065?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- NCT07222995 · 2,900 participants · NA
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI